MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia

por Lerma Clavero, Ada, Boqvist, Paula Lafqvist, Ingelshed, Katrine, Bosdotter, Cecilia, Sedimbi, Saikiran, Jiang, Long, Wermeling, Fredrik, Vojtesek, Borivoj, Lane, David P., Kannan, Pavitra
Publicado 2023

The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy

por Ingelshed, Katrine, Spiegelberg, Diana, Kannan, Pavitra, Påvénius, Linnéa, Hacheney, Jessica, Jiang, Long, Eisinger, Silke, Lianoudaki, Danai, Lama, Dilraj, Castillo, Francisca, Bosdotter, Cecilia, Kretzschmar, Warren W., Al-Radi, Omayma, Fritz, Nicolas, Villablanca, Eduardo J., Karlsson, Mikael C. I., Wermeling, Fredrik, Nestor, Marika, Lane, David P., Sedimbi, Saikiran K.
Publicado 2022